Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 38151631)

  • 1. Unraveling the multifaceted role of EpCAM in colorectal cancer: an integrated review of its function and interplay with non-coding RNAs.
    Jiang X; Wang S; Liang Q; Liu Y; Liu L
    Med Oncol; 2023 Dec; 41(1):35. PubMed ID: 38151631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer.
    Zhang BL; Li D; Gong YL; Huang Y; Qin DY; Jiang L; Liang X; Yang X; Gou HF; Wang YS; Wei YQ; Wang W
    Hum Gene Ther; 2019 Apr; 30(4):402-412. PubMed ID: 30693795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models.
    Zhang Q; Zhang H; Ding J; Liu H; Li H; Li H; Lu M; Miao Y; Li L; Zheng J
    J Immunol Res; 2018; 2018():4263520. PubMed ID: 30410941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses.
    Yang Y; McCloskey JE; Yang H; Puc J; Alcaina Y; Vedvyas Y; Gomez Gallegos AA; Ortiz-Sánchez E; de Stanchina E; Min IM; von Hofe E; Jin MM
    Cancer Immunol Res; 2021 Oct; 9(10):1158-1174. PubMed ID: 34341066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis.
    Ang WX; Li Z; Chi Z; Du SH; Chen C; Tay JC; Toh HC; Connolly JE; Xu XH; Wang S
    Oncotarget; 2017 Feb; 8(8):13545-13559. PubMed ID: 28088790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted integration of EpCAM-specific CAR in human induced pluripotent stem cells and their differentiation into NK cells.
    Tang SY; Zha S; Du Z; Zeng J; Zhu D; Luo Y; Wang S
    Stem Cell Res Ther; 2021 Nov; 12(1):580. PubMed ID: 34802459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epithelial cell adhesion molecule expression (CD326) in cancer: a short review.
    Patriarca C; Macchi RM; Marschner AK; Mellstedt H
    Cancer Treat Rev; 2012 Feb; 38(1):68-75. PubMed ID: 21576002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EpCAM: A new therapeutic target for an old cancer antigen.
    Armstrong A; Eck SL
    Cancer Biol Ther; 2003; 2(4):320-6. PubMed ID: 14508099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significant co-expression of putative cancer stem cell markers, EpCAM and CD166, correlates with tumor stage and invasive behavior in colorectal cancer.
    Kalantari E; Taheri T; Fata S; Abolhasani M; Mehrazma M; Madjd Z; Asgari M
    World J Surg Oncol; 2022 Jan; 20(1):15. PubMed ID: 35016698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lgr5+CD44+EpCAM+ Strictly Defines Cancer Stem Cells in Human Colorectal Cancer.
    Leng Z; Xia Q; Chen J; Li Y; Xu J; Zhao E; Zheng H; Ai W; Dong J
    Cell Physiol Biochem; 2018; 46(2):860-872. PubMed ID: 29627827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solitomab, an epithelial cell adhesion molecule/CD3 bispecific antibody (BiTE), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo.
    English DP; Bellone S; Schwab CL; Roque DM; Lopez S; Bortolomai I; Cocco E; Bonazzoli E; Chatterjee S; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
    Cancer; 2015 Feb; 121(3):403-12. PubMed ID: 25251053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a recombinant anti-VEGFR2-EPCAM bispecific antibody to improve antiangiogenic efficiency.
    Barzaman K; Samadi M; Moradi-Kalbolandi S; Majidzadeh-A K; Salehi M; Jalili N; Jazayeri MH; Khorammi S; Darvishi B; Siavashi V; Shekarabi M; Farahmand L
    Exp Cell Res; 2021 Aug; 405(2):112685. PubMed ID: 34090863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of TINCR expression promotes proliferation, metastasis through activating EpCAM cleavage in colorectal cancer.
    Zhang ZY; Lu YX; Zhang ZY; Chang YY; Zheng L; Yuan L; Zhang F; Hu YH; Zhang WJ; Li XN
    Oncotarget; 2016 Apr; 7(16):22639-49. PubMed ID: 27009809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional Implications of the Dynamic Regulation of EpCAM during Epithelial-to-Mesenchymal Transition.
    Brown TC; Sankpal NV; Gillanders WE
    Biomolecules; 2021 Jun; 11(7):. PubMed ID: 34209658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concise Review: Aggressive Colorectal Cancer: Role of Epithelial Cell Adhesion Molecule in Cancer Stem Cells and Epithelial-to-Mesenchymal Transition.
    Boesch M; Spizzo G; Seeber A
    Stem Cells Transl Med; 2018 Jun; 7(6):495-501. PubMed ID: 29667344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM.
    Casaletto JB; Geddie ML; Abu-Yousif AO; Masson K; Fulgham A; Boudot A; Maiwald T; Kearns JD; Kohli N; Su S; Razlog M; Raue A; Kalra A; HÃ¥kansson M; Logan DT; Welin M; Chattopadhyay S; Harms BD; Nielsen UB; Schoeberl B; Lugovskoy AA; MacBeath G
    Proc Natl Acad Sci U S A; 2019 Apr; 116(15):7533-7542. PubMed ID: 30898885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chimeric Antigen receptor-T (CAR-T) cells targeting Epithelial cell adhesion molecule (EpCAM) can inhibit tumor growth in ovarian cancer mouse model.
    Fu J; Shang Y; Qian Z; Hou J; Yan F; Liu G; Dehua L; Tian X
    J Vet Med Sci; 2021 Mar; 83(2):241-247. PubMed ID: 33328392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer.
    Cao Y; Efetov SK; He M; Fu Y; Beeraka NM; Zhang J; Zhang X; Bannimath N; Chen K
    Arch Immunol Ther Exp (Warsz); 2023 Aug; 71(1):19. PubMed ID: 37566162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Bispecific Antibody Targeting EpCAM and CD3 for Immunotherapy in Ovarian Cancer Ascites: An Experimental Study.
    Li YN; Li YY; Wang SX; Ma XY
    Curr Med Sci; 2023 Jun; 43(3):539-550. PubMed ID: 37119369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinicopathologic, molecular, and prognostic implications of the loss of EPCAM expression in colorectal carcinoma.
    Kim JH; Bae JM; Song YS; Cho NY; Lee HS; Kang GH
    Oncotarget; 2016 Mar; 7(12):13372-87. PubMed ID: 26528695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.